In conclusion, data from our study collectively demonstrated the synergistic effects of PRC2 inhibition and IMiDs for the first time and shed light on the molecular mechanisms by which the combination therapy induced plasma cell differentiation and eventually apoptosis in EZH2 gain-of-function mutant DLBCL. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.